Stephanie Levee

Consultant lobbyist · Kit Public Affairs Inc.

Stephanie Levee of Kit Public Affairs Inc. reported 5 meetings with Members of Parliament since October 2025, with 5 MPs on behalf of 2 clients, most often Vertex Pharmaceuticals (Canada) Inc..

5 MP meetings since October 20255 MPs2 clients at those meetings17 clients registered since January 2025#206 among consultant lobbyists

Former public office: Post-Secondary Co-Operative Educational Intern, Department of Canadian Heritage, until 2018. As the lobbyist reported it to the registry.

Meetings with MPs

5 communication reports naming a Member of Parliament since October 2025, newest first, with the registrant's own description where one was filed.

Date	Client	MPs	Subjects
2026-06-04	Vertex Pharmaceuticals (Canada) Inc. Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.	Juanita Nathan	Health; Industry; Intellectual Property; Science and Technology; Budget
2026-05-26	Canadian Organization for Rare Disorders Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients.	Helena Jaczek	Health; Industry; Intellectual Property; Science and Technology; Budget
2026-03-10	Vertex Pharmaceuticals (Canada) Inc. Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.	Salma Zahid	Health; Industry; Intellectual Property; Science and Technology; Budget
2026-03-10	Vertex Pharmaceuticals (Canada) Inc. Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.	Tom Kmiec	Health; Industry; Intellectual Property; Science and Technology; Budget
2026-03-09	Vertex Pharmaceuticals (Canada) Inc. Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.	Judy A. Sgro	Health; Industry; Intellectual Property; Science and Technology; Budget

Lobbying is legal and registered. A meeting may be about anything; the subjects are the ones the registrant reported. Counts are communication reports in the federal Registry of Lobbyists that name a Member of Parliament or Parliamentary Secretary, one per report, since October 2025. Registrants have until the 15th of the next month to file, so recent weeks are undercounted.

Names are as the registrants filed them; MPs link to their pages when the name matches a sitting MP. Source: Registry of Lobbyists, Office of the Commissioner of Lobbying of Canada (lobbycanada.gc.ca). How this is counted: most active lobbyists.